Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
2.
Dig Liver Dis ; 54(5): 635-641, 2022 05.
Article in English | MEDLINE | ID: mdl-34862115

ABSTRACT

BACKGROUND: Studies to evaluate the use of mycophenolate mofetil (MMF) in inflammatory bowel disease (IBD) are limited after the appearance of biological treatments. AIMS: Our primary objective was to evaluate the effectiveness and safety of MMF in IBD. METHODS: IBD patients who had received MMF were retrieved from the ENEIDA registry. Clinical activity as per the Harvey-Bradshaw Index (HBI), partial Mayo score (pMS), physician global assessment (PGA) and C-reactive protein (CRP) were reviewed at baseline, at 3 and 6 months, and at final follow-up. Adverse events and causes of treatment discontinuation were documented. RESULTS: A total of 83 patients were included (66 Crohn's disease, 17 ulcerative colitis), 90% of whom had previously received other immunosuppressants. In 61% of patients systemic steroids were used at initiation of MMF, and in 27.3% biological agents were co-administered with MMF. Overall clinical effectiveness was observed in 64.7% of the population. At the end of treatment, 45.6% and 19.1% of subjects showed remission and clinical response, respectively. MMF treatment was maintained for a median of 28.9 months (IQR: 20.4-37.5). CONCLUSION: Our study suggests, in the largest cohort to date, that MMF may be an effective alternative to thiopurines and methotrexate in IBD.


Subject(s)
Colitis, Ulcerative , Crohn Disease , Inflammatory Bowel Diseases , Chronic Disease , Colitis, Ulcerative/drug therapy , Crohn Disease/drug therapy , Humans , Inflammatory Bowel Diseases/drug therapy , Mycophenolic Acid/therapeutic use , Registries
3.
Aliment Pharmacol Ther ; 47(5): 605-614, 2018 03.
Article in English | MEDLINE | ID: mdl-29369387

ABSTRACT

BACKGROUND: Onset during old age has been reported in upto 10% of total cases of inflammatory bowel disease (IBD). AIM: To evaluate phenotypic characteristics and the use of therapeutic resources in patients with elderly onset IBD. METHODS: Case-control study including all those patients diagnosed with IBD over the age of 60 years since 2000 who were followed-up for >12 months, identified from the IBD databases. Elderly onset cases were compared with IBD patients aged 18 to 40 years at diagnosis, matched by year of diagnosis, gender and type of IBD (adult-onset). RESULTS: One thousand three hundred and seventy-four elderly onset and 1374 adult-onset cases were included (62% ulcerative colitis (UC), 38% Crohn's disease (CD)). Among UC patients, elderly onset cases had a lower proportion of extensive disease (33% vs 39%; P < 0.0001). In CD, elderly onset cases showed an increased rate of stenosing pattern (24% vs 13%; P < 0.0001) and exclusive colonic location (28% vs 16%; P < 0.0001), whereas penetrating pattern (12% vs 19%; P < 0.0001) was significantly less frequent. Regarding the use of therapeutic resources, there was a significantly lower use of corticosteroids (P < 0.0001), immunosuppressants (P < 0.0001) and anti-TNFs agents (P < 0.0001) in elderly onset cases. Regarding surgery, we found a significantly higher surgery rate among elderly onset UC cases (8.3% vs 5.1%; P < 0.009). Finally, elderly onset cases were characterised by a higher rate of hospitalisations (66% vs 49%; P < 0.0001) and neoplasms (14% vs 0.5%; P < 0.0001). CONCLUSIONS: Elderly onset IBD shows specific characteristics and they are managed differently, with a lower use of immunosuppressants and a higher rate of surgery in UC.


Subject(s)
Inflammatory Bowel Diseases/epidemiology , Inflammatory Bowel Diseases/pathology , Inflammatory Bowel Diseases/therapy , Adolescent , Adult , Age of Onset , Aged , Aged, 80 and over , Case-Control Studies , Disease Progression , Female , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Phenotype , Retrospective Studies , Spain/epidemiology , Young Adult
4.
Am J Gastroenterol ; 112(1): 120-131, 2017 01.
Article in English | MEDLINE | ID: mdl-27958281

ABSTRACT

OBJECTIVES: The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed. METHODS: This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included. RESULTS: A total of 1,055 patients were included. The incidence rate of relapse was 19% and 17% per patient-year in Crohn's disease and ulcerative colitis patients, respectively. In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year. The treatment with adalimumab vs. infliximab (hazard ratio (HR)=1.29; 95% confidence interval (CI)=1.01-1.66), elective discontinuation of anti-TNFs (HR=1.90; 95% CI=1.07-3.37) or discontinuation because of adverse events (HR=2.33; 95% CI=1.27-2.02) vs. a top-down strategy, colonic localization (HR=1.51; 95% CI=1.13-2.02) vs. ileal, and stricturing behavior (HR=1.5; 95% CI=1.09-2.05) vs. inflammatory were associated with a higher risk of relapse in Crohn's disease patients, whereas treatment with immunomodulators after discontinuation (HR=0.67; 95% CI=0.51-0.87) and age (HR=0.98; 95% CI=0.97-0.99) were protective factors. None of the factors were predictive in ulcerative colitis patients. Retreatment of relapse with the same anti-TNF was effective (80% responded) and safe. CONCLUSIONS: The incidence rate of inflammatory bowel disease relapse after anti-TNF discontinuation is relevant. Some predictive factors of relapse after anti-TNF withdrawal have been identified. Retreatment with the same anti-TNF drug was effective and safe.


Subject(s)
Adalimumab/therapeutic use , Antirheumatic Agents/therapeutic use , Colitis, Ulcerative/drug therapy , Crohn Disease/drug therapy , Deprescriptions , Immunologic Factors/therapeutic use , Infliximab/therapeutic use , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Colitis, Ulcerative/physiopathology , Colon , Constriction, Pathologic , Crohn Disease/physiopathology , Disease Progression , Drug-Related Side Effects and Adverse Reactions , Female , Follow-Up Studies , Humans , Ileum , Incidence , Inflammatory Bowel Diseases/drug therapy , Male , Mesalamine/therapeutic use , Methotrexate/therapeutic use , Middle Aged , Proportional Hazards Models , Protective Factors , Recurrence , Remission Induction , Retreatment , Retrospective Studies , Risk Factors , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Young Adult
5.
Aliment Pharmacol Ther ; 43(3): 400-26, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26597122

ABSTRACT

BACKGROUND: Microscopic colitis (MC) is an underdiagnosed inflammatory bowel disease. AIM: To develop an evidence-based clinical practice guide on MC current concepts. METHODS: Literature search was done on the Cochrane Library, EMBASE and MEDLINE electronic databases, which were consulted covering the period up until March 2015. Work groups were selected for each of the reviewed topics, with the purpose of drafting the initial statements and recommendations. They subsequently underwent a voting process based on the Delphi method. Each statement/recommendation was accompanied by the result of the vote the level of evidence, and discussion of the corresponding evidence. The grade of recommendation (GR) using the GRADE approach was established for diagnosis and treatment recommendations. RESULTS: Some key statements and recommendations are: advancing age increases the risk of developing MC, mainly in females. The symptoms of MC and IBS-D may be similar. If MC is suspected, colonoscopy taking biopsies is mandatory. Treatment with oral budesonide is recommended to induce clinical remission in patients with MC. Oral mesalazine is not recommended in patients with collagenous colitis for the induction of clinical remission. The use of anti-TNF-alpha drugs (infliximab, adalimumab) is recommended for the induction of remission in severe cases of MC that fail to respond to corticosteroids or immunomodulators, as an alternative to colectomy. CONCLUSIONS: This is the first consensus paper on MC based on GRADE methodology. This initiative may help physicians involved in care of these patients in taking decisions based on evidence.


Subject(s)
Colitis, Microscopic/epidemiology , Colitis, Microscopic/physiopathology , Adalimumab/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Age Factors , Anti-Inflammatory Agents/therapeutic use , Biopsy , Budesonide/therapeutic use , Colitis, Microscopic/drug therapy , Colonoscopy , Humans , Infliximab/therapeutic use , Sex Factors , Tumor Necrosis Factor-alpha/antagonists & inhibitors
6.
Mater Sci Eng C Mater Biol Appl ; 32(6): 1621-6, 2012 Aug 01.
Article in English | MEDLINE | ID: mdl-24364968

ABSTRACT

Porous Ti6Al4V samples were produced by microsphere sintering. The Zero-Order Reaction Rate Model and Transition State Theory were used to model the sintering process and to estimate the bending strength of the porous samples developed. The evolution of the surface area during the sintering process was used to obtain sintering parameters (sintering constant, activation energy, frequency factor, constant of activation and Gibbs energy of activation). These were then correlated with the bending strength in order to obtain a simple model with which to estimate the evolution of the bending strength of the samples when the sintering temperature and time are modified: σY=P+B·[lnT·t-ΔGa/R·T]. Although the sintering parameters were obtained only for the microsphere sizes analysed here, the strength of intermediate sizes could easily be estimated following this model.


Subject(s)
Titanium/chemistry , Alloys , Microspheres , Particle Size , Porosity , Temperature
7.
Rev Esp Enferm Dig ; 99(5): 264-9, 2007 May.
Article in Spanish | MEDLINE | ID: mdl-17650935

ABSTRACT

OBJECTIVE: To compare the efficacy of early total enteral nutrition (TEN) vs. total parenteral nutrition (TPN) in patients with severe acute pancreatitis (SAP). METHODS: A total of 22 consecutive patients with SAP were randomized to receive TPN (group I) or TEN (group II). SAP was defined applying APACHE II score, C-reactive protein (CRP) measurements and/or Balthazar CT scan score. Acute inflammatory response (CRP, TNF-a, IL-6), visceral proteins (pre-albumin, albumin), complications (systemic inflammatory response syndrome, multiorgan failure, infections), surgical interventions, length of hospital stay and mortality were evaluated. RESULTS: No significant differences were found between the two groups in the APACHE II score, in CRP, TNF-a and IL-6 concentrations or in pre-albumin and albumin levels over the first 10 days. Seven patients in group I and 4 in group II suffered severe complications. Three patients in group I required surgical intervention. Length of hospital stay was alike in the two groups. Two patients from group I died in the course of the hospitalization. CONCLUSIONS: SAP patients with TEN feeding showed a tendency towards a better outcome than patients receiving TPN.


Subject(s)
Enteral Nutrition , Pancreatitis/therapy , Parenteral Nutrition, Total , APACHE , Acute Disease , Adult , Aged , Female , Humans , Length of Stay , Male , Middle Aged , Pancreatitis/blood
8.
Rev. esp. enferm. dig ; 99(5): 264-269, mayo 2007. ilus, tab
Article in Es | IBECS | ID: ibc-056572

ABSTRACT

Objetivo: comparar la eficacia de la instauración precoz de nutrición enteral total (NET) frente a nutrición parenteral total (NPT) en pacientes con pancreatitis aguda grave (PAG). Métodos: estudio prospectivo aleatorio. Se incluyeron consecutivamente 22 pacientes con PAG aplicando los criterios APACHE II, valores de PCR y graduación de Balthazar en la TC. El grupo I (n = 11) recibió NPT y el grupo II (n = 12) NET. Se valoró la respuesta inflamatoria (PCR, TNF-alfa, IL-6), las proteínas viscerales (pre-albúmina, albúmina), la tasa de complicaciones (síndrome de respuesta inflamatoria sistémica, fallo multiorgánico, infecciones), las intervenciones quirúrgicas, la estancia hospitalaria y la mortalidad. Resultados: no hubo diferencias significativas en los primeros 10 días entre los dos grupos en la evolución de los criterios APACHE II, en las concentraciones de PCR, TNF-alfa e IL-6 ni tampoco en los valores de pre-albúmina y albúmina. Siete pacientes del grupo I presentaron complicaciones graves frente a 4 del grupo II. Requirieron intervención quirúrgica 3 pacientes del grupo I. La estancia hospitalaria fue similar en los dos grupos. Dos pacientes del grupo I fallecieron. Conclusiones: se ha observado una tendencia a una mejor evolución de los pacientes con PAG que utilizaron NET frente a los que utilizaron NPT


Objective: to compare the efficacy of early total enteral nutrition (TEN) vs. total parenteral nutrition (TPN) in patients with severe acute pancreatitis (SAP). Methods: a total of 22 consecutive patients with SAP were randomized to receive TPN (group I) or TEN (group II). SAP was defined applying APACHE II score, C-reactive protein (CRP) measurements and/or Balthazar CT scan score. Acute inflammatory response (CRP, TNF-alpha, IL-6), visceral proteins (pre-albumin, albumin), complications (systemic inflammatory response syndrome, multiorgan failure, infections), surgical interventions, length of hospital stay and mortality were evaluated. Results: no significant differences were found between the two groups in the APACHE II score, in CRP, TNF-alpha and IL-6 concentrations or in pre-albumin and albumin levels over the first 10 days. Seven patients in group I and 4 in group II suffered severe complications. Three patients in group I required surgical intervention. Length of hospital stay was alike in the two groups. Two patients from group I died in the course of the hospitalization. Conclusions: SAP patients with TEN feeding showed a tendency towards a better outcome than patients receiving TPN


Subject(s)
Male , Female , Humans , Pancreatitis/therapy , Enteral Nutrition , Parenteral Nutrition, Total , Prospective Studies , C-Reactive Protein/analysis , Interleukin-6/analysis , Serum Albumin/analysis , Tumor Necrosis Factor-alpha/analysis
9.
Dermatology ; 213(3): 234-5, 2006.
Article in English | MEDLINE | ID: mdl-17033174

ABSTRACT

Pyoderma gangrenosum is a reactive inflammatory dermatosis which belongs to the spectrum of neutrophilic dermatoses. Due to a lack of diagnostic criteria, pyoderma gangrenosum is mainly a diagnosis of exclusion. It is rarely observed on the perineum, and vulvar involvement is even less frequent. Collagenous colitis is an idiopathic inflammatory colonic disease that is included in the microscopic colitides. The colonic mucosa and the crypt architecture are preserved but histologic alterations are found. We describe a case of collagenous colitis associated with vulvar pyoderma gangrenosum that improved spectacularly with cyclosporine 3 mg/kg/day and the twice-daily application of topical tacrolimus 0.1%.


Subject(s)
Colitis, Collagenous/complications , Pyoderma Gangrenosum/complications , Vulvar Diseases/complications , Adult , Colitis, Collagenous/diagnosis , Colitis, Collagenous/drug therapy , Cyclosporine/therapeutic use , Female , Humans , Immunosuppressive Agents/therapeutic use , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/drug therapy , Tacrolimus/therapeutic use , Vulvar Diseases/diagnosis , Vulvar Diseases/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...